Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo

Prostate

Volumn 73, Issue 4, 2013, Pages 337-345

  Ewald, Jonathan A ^a,b   Desotelle, Joshua A ^c   Church, Dawn R ^b   Yang, Bing ^a   Huang, Wei ^b   Laurila, Timo A ^a   Jarrard, David F ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

androgen; androgen deprivation; cellular senescence; prostate cancer

Indexed keywords

BETA GALACTOSIDASE; CASPASE 3; CELL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GLB1 PROTEIN; HETEROCHROMATIN PROTEIN 1; HETEROCHROMATIN PROTEIN 1 GAMMA; KI 67 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER REGRESSION; CASTRATION; CELL AGING; CELL STRAIN LNCAP; CELL STRUCTURE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOSIS INHIBITION; MOUSE; NICK END LABELING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INDUCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT;

AGED; ANDROGENS; ANIMALS; CELL AGING; CELL LINE, TUMOR; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872949478     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22571     Document Type: Article

References (33)

1. Denmeade SR, Isaacs JT,. Programmed cell death (apoptosis) and cancer chemotherapy. Cancer Control 1996; 3 (4): 303-309. (Pubitemid 26302008)
2. Smitherman AB, Gregory CW, Mohler JL,. Apoptosis levels increase after castration in the CWR22 human prostate cancer xenograft. Prostate 2003; 57 (1): 24-31. (Pubitemid 37070146)
3. Westin P, Stattin P, Damber JE, Bergh A,. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 1995; 146 (6): 1368-1375.
4. Myers RB, Oelschlager DK, Coan PN, Frost AR, Weiss HL, Manne U, Pretlow TG, Grizzle WE,. Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma. J Urol 1999; 161 (3): 945-949. (Pubitemid 29422413)
5. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI,. Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 1999; 91 (21): 1869-1876.
6. Loda M,. p27KIP1: Androgen regulation and prognostic significance in prostate cancer. Adv Clin Path 2000; 4 (4): 226-232.
7. Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattacharya N, Cirenei N, Loda M,. Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol 2001; 15 (5): 765-782. (Pubitemid 32411315)
8. Ewald JA, Desotelle JA, Wilding G, Jarrard DF,. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010; 102 (20): 1536-1546.
9. Roninson IB,. Tumor cell senescence in cancer treatment. Cancer Res 2003; 63 (11): 2705-2715. (Pubitemid 36667137)
10. Campisi J,. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 2001; 11 (11): S27-S31.
11. Pospelova TV, Demidenko ZN, Bukreeva EI, Pospelov VA, Gudkov AV, Blagosklonny MV,. Pseudo-DNA damage response in senescent cells. Cell Cycle 2009; 8 (24): 4112-4118.
12. Lawless C, Wang C, Jurk D, Merz A, Zglinicki TV, Passos JF,. Quantitative assessment of markers for cell senescence. Exp Gerontol 2010.
13. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O,. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92 (20): 9363-9367.
14. Zhang R, Adams PD,. Heterochromatin and its relationship to cell senescence and cancer therapy. Cell Cycle 2007; 6 (7): 784-789. (Pubitemid 46572614)
15. Ripple MO, Henry WF, Rago RP, Wilding G,. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997; 89 (1): 40-48. (Pubitemid 26428076)
16. Ewald JA, Desotelle JA, Almassi N, Jarrard DF,. Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo. Br J Cancer 2008; 98 (7): 1244-1249. (Pubitemid 351481674)
17. Lamprecht MR, Sabatini DM, Carpenter AE,. CellProfiler: Free, versatile software for automated biological image analysis. Biotechniques 2007; 42 (1): 71-75.
18. Bladou F, Vessella RL, Buhler KR, Ellis WJ, True LD, Lange PH,. Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int J Cancer 1996; 67 (6): 785-790. (Pubitemid 26348806)
19. Huang W, Kanehira K, Drew S, Pier T,. Oncocytoma can be differentiated from its renal cell carcinoma mimics by a panel of markers: An automated tissue microarray study. Appl Immunohistochem Mol Morphol 2009; 17 (1): 12-17.
20. Bringold F, Serrano M,. Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol 2000; 35 (3): 317-329. (Pubitemid 30314689)
21. Lee BY, Han JA, Im JS, Morrone A, Johung K, Goodwin EC, Kleijer WJ, DiMaio D, Hwang ES,. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 2006; 5 (2): 187-195.
22. Haugstetter AM, Loddenkemper C, Lenze D, Grone J, Standfuss C, Petersen I, Dorken B, Schmitt CA,. Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br J Cancer 2010; 103 (4): 505-509.
23. Pernicova Z, Slabakova E, Kharaishvili G, Bouchal J, Kral M, Kunicka Z, Machala M, Kozubik A, Soucek K,. Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2. Neoplasia 2011; 13 (6): 526-536.
24. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP,. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010; 464 (7287): 374-379.
25. Ewald J, Jarrard D,. Decreased Skp2 expression is necessary but not sufficient for therapy-induced senescence in prostate cancer. Trans Oncol 2012; 5 (4): (in press).
26. Iczkowski KA, Huang W, Mazzucchelli R, Pantazis CG, Stevens GR, Montironi R,. Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT. Cancer 2004; 100 (2): 294-299. (Pubitemid 38063637)
27. Litvinov IV, Vander Griend DJ, Antony L, Dalrymple S, De Marzo AM, Drake CG, Isaacs JT,. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci USA 2006; 103 (41): 15085-15090. (Pubitemid 44583168)
28. Shiota M, Yokomizo A, Naito S,. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer. Free Radic Biol Med 2011; 51 (7): 1320-1328.
29. Gregory CW, Johnson RT Jr, Presnell SC, Mohler JL, French FS,. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft. J Androl 2001; 22 (4): 537-548. (Pubitemid 32623073)
30. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek WK, Wang S, Ellwood-Yen K, Wu H, Sawyers CL, Signoretti S, Hahn WC, Loda M, Sellers WR,. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008; 14 (2): 146-155.
31. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW,. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109 (3): 335-346. (Pubitemid 34606876)
32. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW,. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445 (7128): 656-660. (Pubitemid 46232886)
33. Petti C, Molla A, Vegetti C, Ferrone S, Anichini A, Sensi M,. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res 2006; 66 (13): 6503-6511. (Pubitemid 44085604)